Trajectories of Nonmedical Prescription Drug Misuse

非医疗处方药滥用的轨迹

• 批准号: 9908065
• 负责人: SEAN ESTEBAN MCCABE
• 金额: $ 35.88万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-06-01 至 2022-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9908065
• 关键词: 17 year old; Address; Adolescence; Adolescent; Adolescent and Young Adult; Adult; Age; Combined Modality Therapy; Data; Development; Disease; Drug abuse; Employment; Equation; Exposure to; Future; Growth; Health; Health Professional; Individual; Investigation; Knowledge; Life; Longitudinal Studies; Measures; Medical; Modality; Modeling; Monitor; Parents; Pattern; Pharmaceutical Preparations; Prescription opioid overdose; Prevention; Research; Research Design; Risk; Risk Factors; Sample Size; Sampling; Schedule; Structure; Substance Use Disorder; Symptoms; Techniques; Time; Tranquilizing Agents; United States National Institutes of Health; Weight; Work; adverse outcome; base; clinical practice; cohort; functional outcomes; misuse of prescription only drugs; nonmedical use; prescription drug abuse; prescription opioid; prescription opioid misuse; protective factors; rate of change; response; secondary analysis; sedative; theories; twelfth grade; young adult

PROJECT SUMMARY/ABSTRACT In response to PAR-18-062: Accelerating the Pace of Drug Abuse Research Using Existing Data, this competing renewal “Trajectories of Nonmedical Prescription Drug Misuse” builds on our parent R01 and proposes to use national data to assess the longitudinal relationships among trajectories of medical and nonmedical use of prescription medications, functional outcomes and adverse consequences from adolescence (age 18) to middle adulthood (age 50). The proposed research will focus on prescription opioids, sedatives/tranquilizers, and stimulants because the medical and nonmedical use of these medications and related consequences have increased over the past three decades in the U.S. To date, no national studies have examined the impact of attrition on medical and nonmedical use estimates in longitudinal studies. Moreover, national studies fail to examine long-term functional outcomes or adverse outcomes associated with different trajectories of medical and nonmedical use of prescription medications. More longitudinal studies of adolescents followed into middle adulthood are needed because adults are more likely to be prescribed scheduled medications and often assume greater life/work responsibilities. As a result, we propose secondary analyses focusing primarily on the MTF longitudinal panel sample, which features 11 separate cohorts of approximately 26,400 high school seniors (modal age 18) who were followed 1-2 years (ages 19-20), 3-4 years (ages 21-22), 5-6 years (ages 23-24), 7-8 years (ages 25-26), 9-10 years (ages 27-28), 11-12 years (ages 29- 30), 17 years (age 35), 22 years (age 40), 27 years (age 45), and 32 years later (age 50) resulting in 11 overall waves of data. The MTF data provide a unique opportunity with sufficient measures and sample sizes for examining relationships over 32 years and to meet the objectives of our study, which aims to: 1) estimate the bias in estimated rates of medical and nonmedical use of prescription opioids, sedatives/tranquilizers, and stimulants at different developmental periods and in estimated rates of change over time in medical and nonmedical use due to differential attrition, by comparing and evaluating alternative weighting and imputation approaches; 2) identify the trajectories of medical and nonmedical use of prescription opioids, sedatives/tranquilizers, and stimulants based on multiple waves of longitudinal data from adolescence (age 18) to middle adulthood (age 50); 3) use growth mixture modeling to evaluate whether subject-specific trajectories of nonmedical and medical use of prescription opioids, sedatives/tranquilizers, and stimulants from adolescence to age 45 are predictive of functional outcomes (e.g., educational attainment) and adverse consequences (e.g., SUD symptoms) at age 50; and 4) examine the adolescent risk and protective factors for trajectories of medical and nonmedical use of prescription medications that are associated with poor functional outcomes and adverse consequences in middle adulthood using a theory-based developmental model.

项目摘要/摘要 为了回应PAR-18-062：利用现有数据加快药物滥用研究的步伐，这 竞争性更新《非医疗处方药滥用轨迹》建立在我们的母公司R01和 建议使用国家数据来评估医疗和医疗发展轨迹之间的纵向关系 处方药的非医疗使用、功能结果和不良后果 青春期(18岁)至中年(50岁)。拟议的研究将集中在处方阿片类药物上， 镇静剂/镇静剂和兴奋剂，因为这些药物的医疗和非医疗用途 在过去的三十年里，相关的后果在美国有所增加，到目前为止，还没有全国性的研究 在纵向研究中检查了自然减员对医疗和非医疗用途估计的影响。 此外，国家研究未能检查与以下疾病相关的长期功能后果或不良后果 处方药的医疗和非医疗使用的不同轨迹。更多的纵向研究 青少年需要被跟踪到中年，因为更有可能给成年人开处方 定期服药，往往承担更大的生活/工作责任。因此，我们建议将 分析主要集中在MTF纵向面板样本上，该样本具有11个独立的队列 大约26,400名高三学生(18岁)被跟踪1-2年(19-20岁)，3-4年 5-6岁(23-24岁)、7-8岁(25-26岁)、9-10岁(27-28岁)、11-12岁(29-28岁) 30岁)，17岁(35岁)，22岁(40岁)，27岁(45岁)，32年后(50岁)，总共有11人 一连串的数据。MTF数据提供了一个独特的机会，具有足够的衡量标准和样本量 审查32年来的关系，并达到我们研究的目标，其目的是：1)估计 处方类阿片类药物、镇静剂/镇静剂的医疗和非医疗使用率估计值存在偏差，以及 不同发育期的兴奋剂以及估计的医学和药物随时间的变化率 通过比较和评估不同的加权和归算，由于不同的磨损而导致的非医疗用途 方法；2)确定处方类阿片的医疗和非医疗使用轨迹， 基于青春期(18岁)多波纵向数据的镇静剂/镇静剂和兴奋剂 到中年(50岁)；3)使用生长混合模型来评估特定于受试者的轨迹 处方类阿片类药物、镇静剂/镇静剂和兴奋剂的非医疗和医疗用途 青春期到45岁预示着功能结果(例如，教育程度)和不利的 50岁时的后果(例如，SUD症状)；以及4)检查青少年的风险和保护因素 与功能不良相关的处方药的医疗和非医疗使用轨迹 以理论为基础的发展模型在成年中期的结果和不良后果。